X4 PHARMACEUTICALS, INC Increase (Decrease) in Accrued Liabilities
X4 PHARMACEUTICALS, INC (XFOR) reported Increase (Decrease) in Accrued Liabilities of -$4.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$2.93M, a 1391.19% decline year-over-year.
- X4 PHARMACEUTICALS, INC increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$1.55M.
- X4 PHARMACEUTICALS, INC increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $2.17M, a 35.12% decline year-over-year.
- X4 PHARMACEUTICALS, INC increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $3.37M.
- X4 PHARMACEUTICALS, INC increase (decrease) in accrued liabilities for fiscal 2025 was -$2.02M, a 128.25% decline from fiscal 2024.
- X4 PHARMACEUTICALS, INC increase (decrease) in accrued liabilities for fiscal 2024 was $7.17M, a 345.83% increase from fiscal 2023.
- X4 PHARMACEUTICALS, INC increase (decrease) in accrued liabilities for fiscal 2023 was $1.61M, a 57.72% decline from fiscal 2022.
- X4 PHARMACEUTICALS, INC increase (decrease) in accrued liabilities for fiscal 2022 was $3.80M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$4.48M 10-Q · filed 2026-08-06 | -$2.31M derived: sum of 3 quarters · filed 2026-08-06 | $1.05M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$1.55M 10-Q · filed 2026-05-06 | $616.00K derived: sum of 2 quarters · filed 2026-05-06 | $3.98M derived: sum of 3 quarters · filed 2026-05-06 | $4.21M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $5.53M derived: sum of 2 quarters · filed 2026-03-17 | $5.76M derived: sum of 3 quarters · filed 2026-08-06 | -$2.02M 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | $3.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.59M derived: sum of 2 quarters · filed 2026-08-06 | -$4.19M 10-Q · filed 2025-11-05 | -$853.00K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $227.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$7.55M 10-Q · filed 2026-08-06 | -$4.22M derived: sum of 3 quarters · filed 2026-08-06 | -$4.39M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$7.78M 10-Q · filed 2026-05-06 | -$4.45M derived: sum of 2 quarters · filed 2026-05-06 | -$4.61M derived: sum of 3 quarters · filed 2026-05-06 | -$1.88M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $3.17M derived: sum of 2 quarters · filed 2026-03-17 | $5.91M derived: sum of 3 quarters · filed 2026-03-17 | $7.17M 10-K · filed 2026-03-17 | ||||
| 2024-09-30 | -$169.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.57M derived: sum of 2 quarters · filed 2025-11-05 | $3.83M 10-Q · filed 2025-11-05 | -$211.00K derived: sum of 4 quarters · filed 2026-03-17 | ||||
| 2024-06-30 | $2.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $4.00M 10-Q · filed 2025-08-08 | -$42.00K derived: sum of 3 quarters · filed 2026-03-17 | $585.00K derived: sum of 4 quarters · filed 2026-03-17 | ||||
| 2024-03-31 | $1.26M 10-Q · filed 2025-05-01 | -$2.78M derived: sum of 2 quarters · filed 2026-03-17 | -$2.15M derived: sum of 3 quarters · filed 2026-03-17 | $2.38M derived: sum of 4 quarters · filed 2026-03-17 | ||||
| 2023-12-31 | -$4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$3.42M derived: sum of 2 quarters · filed 2026-03-17 | $1.11M derived: sum of 3 quarters · filed 2026-03-17 | $1.61M 10-K · filed 2026-03-17 | ||||
| 2023-09-30 | $627.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $5.16M derived: sum of 2 quarters · filed 2024-11-13 | $5.65M 10-Q · filed 2024-11-13 | $8.15M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2023-06-30 | $4.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.02M 10-Q · filed 2024-08-08 | $7.52M derived: sum of 3 quarters · filed 2025-03-26 | $8.18M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2023-03-31 | $496.00K 10-Q · filed 2024-05-07 | $2.99M derived: sum of 2 quarters · filed 2025-03-26 | $3.65M derived: sum of 3 quarters · filed 2025-03-26 | $5.28M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2022-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $3.15M derived: sum of 2 quarters · filed 2025-03-26 | $4.79M derived: sum of 3 quarters · filed 2025-03-26 | $3.80M 10-K · filed 2025-03-26 | ||||
| 2022-09-30 | $654.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.29M derived: sum of 2 quarters · filed 2023-11-09 | $1.30M 10-Q · filed 2023-11-09 | $84.00K derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-06-30 | $1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $651.00K 10-Q · filed 2023-08-10 | -$570.00K derived: sum of 3 quarters · filed 2024-03-21 | $1.35M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-03-31 | -$984.00K 10-Q · filed 2023-05-04 | -$2.21M derived: sum of 2 quarters · filed 2024-03-21 | -$283.00K derived: sum of 3 quarters · filed 2024-03-21 | -$350.00K derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2021-12-31 | -$1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $701.00K derived: sum of 2 quarters · filed 2024-03-21 | $634.00K derived: sum of 3 quarters · filed 2024-03-21 | -$152.00K 10-K · filed 2024-03-21 | ||||
| 2021-09-30 | $1.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.85M derived: sum of 2 quarters · filed 2022-11-03 | $1.07M 10-Q · filed 2022-11-03 | $864.00K derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-06-30 | -$67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$853.00K 10-Q · filed 2022-08-04 | -$1.06M derived: sum of 3 quarters · filed 2023-03-21 | -$878.00K derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-03-31 | -$786.00K 10-Q · filed 2022-05-12 | -$991.00K derived: sum of 2 quarters · filed 2023-03-21 | -$811.00K derived: sum of 3 quarters · filed 2023-03-21 | $1.40M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2020-12-31 | -$205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | -$25.00K derived: sum of 2 quarters · filed 2023-03-21 | $2.19M derived: sum of 3 quarters · filed 2023-03-21 | $1.52M 10-K · filed 2023-03-21 | ||||
| 2020-09-30 | $180.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.39M derived: sum of 2 quarters · filed 2021-11-04 | $1.72M 10-Q · filed 2021-11-04 | $2.48M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-06-30 | $2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $1.54M 10-Q · filed 2021-08-03 | $2.30M derived: sum of 3 quarters · filed 2022-03-17 | $2.86M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-03-31 | -$668.00K 10-Q · filed 2021-05-06 | $87.00K derived: sum of 2 quarters · filed 2022-03-17 | $649.00K derived: sum of 3 quarters · filed 2022-03-17 | $1.56M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2019-12-31 | $755.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.32M derived: sum of 2 quarters · filed 2022-03-17 | $2.23M derived: sum of 3 quarters · filed 2022-03-17 | $160.00K 10-K · filed 2022-03-17 | ||||
| 2019-09-30 | $562.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.48M derived: sum of 2 quarters · filed 2020-11-05 | -$595.00K 10-Q · filed 2020-11-05 | -$220.00K derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2019-06-30 | $915.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$1.16M 10-Q · filed 2020-08-04 | -$782.00K derived: sum of 3 quarters · filed 2021-03-19 | -$61.00K derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2019-03-31 | -$2.07M 10-Q · filed 2020-05-07 | -$1.70M derived: sum of 2 quarters · filed 2021-03-19 | -$976.00K derived: sum of 3 quarters · filed 2021-03-19 | -$763.00K derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2018-12-31 | $375.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $1.10M derived: sum of 2 quarters · filed 2021-03-19 | $1.31M derived: sum of 3 quarters · filed 2021-03-19 | $1.55M 10-K · filed 2021-03-19 | -$1.68M 10-K · filed 2019-03-11 | |||
| 2018-09-30 | $721.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $934.00K derived: sum of 2 quarters · filed 2019-11-07 | $1.17M 10-Q · filed 2019-11-07 | -$2.68M 10-Q · filed 2018-11-09 | $520.00K derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2018-06-30 | $213.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $453.00K 10-Q · filed 2019-08-07 | -$1.89M 10-Q · filed 2018-08-13 | -$201.00K derived: sum of 3 quarters · filed 2020-03-12 | $428.00K derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2018-03-31 | $240.00K 10-Q · filed 2019-05-15 | -$654.00K 10-Q · filed 2018-05-10 | -$414.00K derived: sum of 2 quarters · filed 2020-03-12 | $215.00K derived: sum of 3 quarters · filed 2020-03-12 | $505.00K derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2017-12-31 | -$654.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$25.00K derived: sum of 2 quarters · filed 2020-03-12 | $265.00K derived: sum of 3 quarters · filed 2020-03-12 | $1.41M 10-K · filed 2020-03-12 | $3.29M 10-K · filed 2019-03-11 | |||
| 2017-09-30 | $629.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $919.00K derived: sum of 2 quarters · filed 2018-11-09 | $2.06M 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | $290.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $1.43M 10-Q · filed 2018-08-13 | ||||||
| 2017-03-31 | $1.14M 10-Q · filed 2018-05-10 | |||||||
| 2016-12-31 | $521.00K 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |